Advanced Glycation End Products and Cardiovascular Disease

被引:57
|
作者
Peppa, Melpomeni [1 ]
Raptis, Sotirios A. [1 ]
机构
[1] Attikon Univ Hosp, Res Inst & Diabet Ctr & Hel lenic Natl Diabet Ctr, Dept Internal Medicine Propaedeut 2, Endocrine Unit, Athens, Greece
关键词
Cardiovascular disease; Atherosclerosis; Oxidative stress; Inflammation; Arterial stiffening; Endothelium; Diet; Advanced glycation end products; AGEs; AGE-receptors; AGE-inhibitors; AGE-breakers;
D O I
10.2174/157339908784220732
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cardiovascular disease (CVD) is the leading cause of mortality worldwide. Advanced glycation end products [AGEs] seem to play an important role for the development and/or progression of CVD mainly through induction of oxidative stress and inflammation. AGEs are a heterogenous group of molecules formed by the nonenzymatic reaction of reducing sugars with amino acids of proteins, lipids and nucleic acids. Recent studies suggest that in addition to those endogenously formed, diet constitutes an important exogenous source of AGEs. Diet-derived AGEs contribute to the whole body AGE pool and the AGE-related pathology. Recent in vitro and in vivo studies revealed significant correlations between diet-derived AGEs and several risk factors and/ or markers of CVD, suggesting the dietary AGEs restriction as a promising therapeutic intervention.
引用
收藏
页码:92 / 100
页数:9
相关论文
共 50 条
  • [41] LOW SERUM LEVELS OF SOLUBLE RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS IS NOT AN UNIVERSAL BIOMARKER FOR CARDIOVASCULAR DISEASE
    Prasad, K.
    CARDIOLOGY, 2017, 137 : 267 - 267
  • [42] Generation and Accumulation of Various Advanced Glycation End-Products in Cardiomyocytes May Induce Cardiovascular Disease
    Takata, Takanobu
    Inoue, Shinya
    Masauji, Togen
    Miyazawa, Katsuhito
    Motoo, Yoshiharu
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (13)
  • [43] Therapeutic Interventions for Advanced Glycation-End Products and its Receptor-Mediated Cardiovascular Disease
    Prasad, Kailash
    Tiwari, Shuchita
    CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (06) : 937 - 943
  • [44] Advanced glycation end products and the kidney
    Bohlender, JM
    Franke, S
    Stein, G
    Wolf, G
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2005, 289 (04) : F645 - F659
  • [45] Advanced glycation end products in end-stage renal disease and their removal
    Schinzel, R
    Münch, G
    Heidland, A
    Sebekova, K
    NEPHRON, 2001, 87 (04) : 295 - 303
  • [46] Advanced glycation end products in uremia
    Henle, T
    Miyata, T
    ADVANCES IN RENAL REPLACEMENT THERAPY, 2003, 10 (04): : 321 - 331
  • [47] Advanced Glycation End Products and Psoriasis
    Maurelli, Martina
    Gisondi, Paolo
    Girolomoni, Giampiero
    VACCINES, 2023, 11 (03)
  • [48] Advanced glycation end products and allergy
    Masako Toda
    Michael Hellwig
    Hiroyuki Hattori
    Thomas Henle
    Stefan Vieths
    Allergo Journal International, 2023, 32 (7) : 296 - 301
  • [49] Advanced glycation end products and nutrition
    Krajcovicová-Kudlácková, M
    Sebeková, K
    Schinzel, R
    Klvanová, J
    PHYSIOLOGICAL RESEARCH, 2002, 51 (03) : 313 - 316
  • [50] Advanced glycation end products as biomarkers in systemic diseases: premises and perspectives of salivary advanced glycation end products
    Babtan, Anida M.
    Ilea, Aranka
    Bosca, Bianca A.
    Crisan, Maria
    Petrescu, Nausica B.
    Collino, Massimo
    Sainz, Rosa M.
    Gerlach, Jared Q.
    Campian, Radu S.
    BIOMARKERS IN MEDICINE, 2019, 13 (06) : 479 - 495